A 63-year-old man was diagnosed with diabetes mellitus at 42 years of age. He subsequently exhibited poor blood glucose control for a prolonged period, and his renal failure worsened. He therefore underwent hemodialysis and abdominal magnetic resonance imaging, which revealed a mass in the pancreatic tail. The immunoreactive insulin and C-peptide immunoreactivity levels were significantly elevated, and the results of a fasting test led to a diagnosis of insulinoma. The patient received treatment with oral diazoxide and continuous glucose monitoring (CGM), which resulted in the resolution of the hypoglycemia. This is a rare case of renal failure in which the CGM findings showed improvements in the blood glucose level after diazoxide administration.
Introduction
Insulinoma is a functional tumor derived from pancreatic β cells characterized by autonomous insulin secretion. With an incidence of around 1 to 4 per million persons, insulinoma presents with hypoglycemic symptoms caused by the overproduction of insulin (1, 2) . The disease is distinguished by the onset of central nervous system (CNS) symptoms upon fasting, including impaired consciousness, convulsions and abnormal behavior (3, 4) . Radical treatment for insulinoma generally consists of surgical resection, although pharmacotherapy is usually selected if tumor localization or surgical resection prove difficult due to the presence of multiple complications or if the patient does not wish to undergo surgery, as in the present case (5) . This report describes our experience in treating a patient with chronic renal failure and a history of diabetes mellitus who developed insulinoma and chose to receive pharmacotherapy with diazoxide. There is no current literature regarding the treatment of dialysis patients with diazoxide. We therefore present this very rare case in which we carefully monitored the patient's blood glucose kinetics using continuous glucose monitoring (CGM).
Case Report
The patient was a 63-year-old man who had been diagnosed with diabetes mellitus at 42 years of age. Although his condition initially improved with only diet therapy, the diabetes mellitus worsened (HbA1c: 15%) at 50 years of age, and he began taking oral medications. At 55 years of age, the HbA1c level decreased to below 6%, and the oral therapy was discontinued. The patient then returned to treatment with diet therapy alone, and his progress was followed. However, around January 2012, he began to experience hypoglycemic symptoms in the early morning, and, in August of the same year, he suffered from impaired consciousness due to hypoglycemia and was taken to the local hospital via ambulance. Several years earlier, he had been diagnosed with chronic renal failure and started on hemodialysis. Blood test results obtained upon admission to the local hospital in 2012 showed an elevated blood immunoreactive insulin (IRI) level of 42.9 μIU/mL, and abdominal Upon admission to our hospital, the patient had a height of 174 cm, body weight of 77.0 kg, body mass index (BMI) of 25.4 kg/m 2 , blood pressure of 146/82 mmHg and body temperature of 36.6 . The physical findings did not show any obvious abnormalities. In addition, neurological examinations did not disclose any glove or stocking type disturbances of touch, and the pain and vibratory sensation in the peripheral extremities was normal. Although the deep tendon reflexes were not diminished, preproliferative retinopathy was detected on an ophthalmological examination. The patient also experienced occasional episodes of diaphoresis and unconsciousness while fasting in the hospital, which were immediately relieved by the administration of glucose. The fasting blood test results on admission (Table) showed a blood glucose level of 76 mg/dL, with elevated IRI (20.2 μU/mL) and C-peptide immunoreactivity (CPR) (18.8 ng/ mL) levels due to the effects of renal failure. The possibility of secondary hypoglycemia resulting from adrenal or hepatic insufficiency was excluded. The blood IRI, CPR and proinsulin levels were significantly elevated, while anti-insulin antibodies were negative. Although the blood glucose level fell to 44 mg/dL, the IRI and CPR values remained high at 30 μU/mL and 14.98 ng/mL, respectively, 13 hours after the start of a fasting test. Abdominal contrast-enhanced computed tomography (CT) and endoscopic ultrasound (EUS) demonstrated early dense staining of a large 23-mm mass in the tail of the pancreas (Fig. 1) . A pathological examination using EUS-guided fine-needle aspiration detected cells positively stained with synaptophysin and Ki-67, leading to a diagnosis of a Grade 1 pancreatic neuroendocrine tumor (P-NET) (Fig. 2) . Based on these findings, the patient was diagnosed with insulinoma classified as a functional P-NET. The possibility of multiple endocrine neoplasia was ruled out due to the lack of additional concurrent endocrine disorders.
In preparation for possible surgical treatment, angiography and arterial stimulation venous sampling (ASVS) were considered for a localization diagnosis. Although both we and the surgeons repeatedly informed the patient that surgical resection is the primary treatment for insulinoma, he did not consent to undergo surgery. Therefore, oral diazoxide was initiated at a low dose of 25 mg/day. After increasing the diazoxide dose to 250 mg/day, CGM (using the iPro 2, Medtronic MiniMed Inc., Northridge, USA) was used to measure the 24-hour blood glucose level over one week, and the results were compared with the baseline values recorded for the same duration (Fig. 3) . Consequently, the findings showed that the patient did not experience any hypoglycemic symptoms late at night or early in the morning, even after discontinuing his pre-bedtime snack (100-160 kcal/night) prior to diazoxide administration. The diazoxide therapy did not have any marked effect on the dialysis findings, and a stable increase was noted in the blood glucose level. The patient was subsequently released from the hospital and started on ambulatory treatment while gradually reducing the dose of diazoxide. Six months after the initiation of oral treatment with diazoxide at a dose of 150 mg/day, the blood test results showed a trend toward improvement [HbA1c: 4.7%, glycated albumin (GA): 13.6%], and he no longer exhibited any hypoglycemic symptoms.
Discussion
Neuroendocrine tumors (NETs) have garnered much attention in recent years due to a surge in their global prevalence (6) . In particular, the use of a somatostatin analogue and inhibitor of mammalian target of rapamycin (mTOR) has been shown to improve P-NET symptoms and reduce the tumor size in patients with gastroenteropancreatic NETs (7). The World Health Organization (WHO) updated its classification of NETs in 2010, placing a special emphasis on the Ki67 index in contrast to the conventional parameters of histopathological differentiation and biological malignancy (8) . The present case report describes our experience with using diazoxide to treat a P-NET Grade 1 insulinoma in a dialysis patient after monitoring his blood glucose kinetics with CGM. The first-line treatment for insulinoma is surgical resection. However, if localization proves difficult and/or surgical procedures are not considered feasible, pharmacotherapy with diazoxide or somatostatin analogues is often selected (5, 9) . In the current case, we chose to administer diazoxide to improve the symptoms of hypoglycemia based on the findings of Stehouwer et al. showing that the use of somatostatin analogue therapy may be associated with the onset of clinically important hypoglycemia during which counterregulatory hormone secretion is attenuated (10). Diazoxide inhibits insulin release by opening adenosine triphosphate (ATP)-sensitive K + channels, which causes hyperpolarization of the β-cell membrane, with a reduced rate of opening of voltage-dependent Ca 2+ channels and the eventual elimination of Ca 2+ influx (11, 12) . Adverse reactions in the form of fluid retention and edema have also been reported, highlighting the need for strict caution in patients with a decreased cardiac or renal function (13) . For this reason, we exercised caution when increasing the current patient's dose of treatment. Consequently, CGM showed that the serious hypoglycemic attacks resolved with the oral administration of diazoxide at a dose of 250 mg/ day. Gill et al. (13) reported that symptoms improved and/or resolved in 59% of 40 insulinoma patients who received diazoxide over a period of approximately seven years. In Japan, diazoxide has been found to be effective in treating patients with a form of hyperinsulinemic hypoglycemia known as nesidioblastosis (14) . These findings suggest that diazoxide may also be useful for controlling and maintaining blood glucose and ensuring the quality of life (QOL) in patients with insulinoma indicative of a form of hyperinsulinemic hypoglycemia that is not indicated for surgery. In chronic renal failure patients, such as the present patient, reduced metabolic clearance is known to result in an elevated IRI level (15) . Therefore, it is difficult to diagnose insulinoma based solely on the detection of an elevated IRI value under conditions of hypoglycemia. Moreover, diazoxide is excreted via the kidneys, and the administration of this drug in renal failure patients thus warrants careful consideration (16) .
In the present study, an insulinoma was accurately diagnosed using CT and EUS-guided fine-needle aspiration, and the effects of diazoxide therapy were confirmed with CGM. This is the first reported case in which diazoxide was used to treat insulinoma in a chronic renal failure patient on hemodialysis by carefully adjusting the dose of the drug.
Furthermore, it has been reported that, in diabetic patients, the incidence of insulinoma is quite low compared to the general population (17) , and there are few case reports in the medical literature on this subject (18) . A retrospective study conducted at the Mayo Clinic reported only one case of insulinoma concomitant with diabetes among 313 cases recorded between 1927 and 1992 (19) . Meanwhile, Ishii et al. reported only one diabetic patient among 443 cases of insulinoma (17, 20) . Our current case is very rare in that, although the patient had diabetes mellitus with an HbA1c level of 15%, the subsequent onset of insulinoma-induced hypoglycemia may have been responsible for the dramatic improvement observed in the HbA1c value.
This report describes our experience in treating a maintenance dialysis patient with a history of diabetes mellitus who opted to undergo pharmacotherapy with diazoxide after developing insulinoma. In this case, we successfully administered diazoxide by carefully monitoring the patient's blood glucose kinetics before and after diazoxide administration using CGM.
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